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Abstract
Background: Neurotrophins and their receptors are key molecules in the regulation of neuronal differentiation and
survival. They mediate the survival of neurons during development and adulthood and are implicated in synaptic
plasticity. The human neurotrophin-3 receptor gene NTRK3 yields two major isoforms, a full-length kinase-active
form and a truncated non-catalytic form, which activates a specific pathway affecting membrane remodeling and
cytoskeletal reorganization. The two variants present non-overlapping 3’UTRs, indicating that they might be
differentially regulated at the post-transcriptional level. Here, we provide evidence that the two isoforms of NTRK3
are targeted by different sets of microRNAs, small non-coding RNAs that play an important regulatory role in the
nervous system.
Results: We identify one microRNA (miR-151-3p) that represses the full-length isoform of NTRK3 and four
microRNAs (miR-128, miR-485-3p, miR-765 and miR-768-5p) that repress the truncated isoform. In particular, we
show that the overexpression of miR-128 - a brain enriched miRNA - causes morphological changes in SH-SY5Y
neuroblastoma cells similar to those observed using an siRNA specifically directed against truncated NTRK3, as well
as a significant increase in cell number. Accordingly, transcriptome analysis of cells transfected with miR-128
revealed an alteration of the expression of genes implicated in cytoskeletal organization as well as genes involved
in apoptosis, cell survival and proliferation, including the anti-apoptotic factor BCL2.
Conclusions: Our results show that the regulation of NTRK3 by microRNAs is isoform-specific and suggest that
neurotrophin-mediated processes are strongly linked to microRNA-dependent mechanisms. In addition, these
findings open new perspectives for the study of the physiological role of miR-128 and its possible involvement in
cell death/survival processes.
Background
Neurotrophins are a family of growth factors that play
important roles in the nervous system. They exert mul-
tiple functions, being crucial for the survival and main-
tenance of the central and peripheral nervous system as
well as in axon and dendrite patterning. Recent evidence
has shown that neurotrophins also act as modulators in
synaptic plasticity and are consequently involved in cog-
nitive processes, learning and memory formation [1].
In mammals, the neurotrophin family is composed of
four members: nerve growth factor (NGF), brain-derived
neurotrophic factor (BDNF), neurotrophin-3 (NT3), and
neurotrophin-4/5 (NT4/5). Each member binds with
high affinity to a specific neurotrophic tyrosine kinase
(NTRK) receptor: NGF is the preferred ligand for
NTRK1 (TrkA), BDNF and NT4/5 for NTRK2 (TrkB),
and NT3 for NTRK3 (TrkC) [2]. Upon neurotrophin-
induced stimulation, NTRK receptors can activate the
Ras/MAPK pathway, the PI3K (phosphoinositide 3-
kinase) pathway, and/or PLC-g1 (phospholipase C
gamma 1)-dependent signaling, respectively promoting
cell survival, differentiation and activity-dependent
plasticity.
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Neurotrophins exert neuroprotective activity against
different paradigms of neuronal cell death [3-5], linking
neurotrophic factors, in particular NGF, to neurodegen-
erative disorders [6]. Neurotrophins and their receptors
have also been implicated in the etiology of psychiatric
and mood disorders, often in a dosage-dependent man-
ner [7]. As for many other growth factors, the deregula-
tion of neurotrophin signal transduction is involved in
several types of cancers, where NTRK receptor activa-
tion can either support or suppress tumor growth. This
is the case for example of NTRK3, which is highly
expressed in neuroblastomas with good prognosis and
highly correlates with patient survival [8].
The human NTRK3 gene is located on chromosome
15q25 and spans ~380 kb of genomic DNA (chr15:
86,220,992-86,600,665, March 2006, hg18). It contains
19 introns and undergoes alternative splicing. In
humans, three transcript variants have been well charac-
terized: a full-length catalytic form (NM_002530) con-
taining a tyrosine kinase (TK) domain, a full-length
isoform (NM_001012338) with an insertion of 14 amino
acids in the TK domain - which is less abundant and
shows reduced signaling potential [9] - and a single
non-catalytic truncated form (NM_001007156) that
completely lacks the TK domain [10]. Two major pro-
tein isoforms have correspondingly been detected in
human brain samples: the full-length, kinase-active 150-
kDa receptor (FL-NTRK3) and a truncated non-catalytic
isoform (TR-NTRK3) of 50 kDa [11]. The main function
that has long been attributed to the truncated isoform is
the inhibition of catalytic receptors, which is achieved
through a dominant-negative or a ligand-sequestering
mechanism. However, a recent work has identified a
new signaling pathway activated by the truncated iso-
form, which links NT3 to downstream molecules affect-
ing membrane remodeling, cytoskeletal reorganization
and cell movement, such as the scaffold protein tamalin,
the Rac1 GTPase and the adenosine diphosphate-ribosy-
lation factor Arf6 [12].
In humans, the full-length receptor is expressed at low
but relatively constant levels throughout development,
while the truncated receptor is expressed at moderate
levels early in development and increases to reach mature
levels by adolescence. In contrast, both full-length and
truncated transcripts are uniformly expressed throughout
postnatal life and decline in ageing [11]. This discrepancy
between changes in protein and mRNA levels of NTRK3
suggests that post-transcriptional regulation may play a
role in controlling the expression of the two isoforms, in
addition to alternative splicing.
MicroRNAs (miRNAs) are post-transcriptional regula-
tors that have been shown to play a key role in the
nervous system. The distribution of miRNAs in the
developing and adult nervous system is spatially and/or
temporally restricted [13], indicating that they may con-
tribute to the fine-tuning of neuronal gene expression.
Structurally, mature miRNAs are small RNAs of
approximately 22 nucleotides in length, and regulate
gene expression by means of partial complementarity to
miRNA binding sites located in the 3’ untranslated
regions (3’UTRs) of target mRNAs [14]. In particular,
perfect complementarity between nucleotide #2 through
#7 or #8 at the 5’ end of the mature miRNA - the so-
called seed region - and the 3’UTR of genes is consid-
ered determinant for successful binding [15]. Genes
with long 3’UTRs are more prone to miRNA-mediated
regulation compared with genes with short 3’UTRs,
which tend to be specifically deprived of miRNA target
sites [16]. Interestingly, full-length and truncated
NTRK3 transcripts show different 3’UTR regions that do
not overlap, supporting the hypothesis that the two iso-
forms may be differentially regulated by miRNAs.
Furthermore, it has recently been shown that miRNAs
miR-9 and miR-125a/b are able to specifically regulate
the expression of the truncated isoform of the NTRK3
receptor [17].
Only one study has so far analyzed the contribution of
miRNAs to determining the balance between different
variants of the same gene [18]. Here, we show that the
full-length and truncated isoforms of NTRK3 are regu-
lated by different sets of miRNAs. In addition, we
demonstrate that, among the miRNAs that inhibit the
truncated isoform, the overexpression of miR-128 - a
brain-enriched miRNA - in SH-SY5Y neuroblastoma
cells alters the expression profile of genes involved in
cytoskeletal organization and of genes related with
apoptosis and cell cycle regulation, including the anti-
apoptotic factor BCL2.
Methods
Firefly luciferase constructs
The 3’UTRs of the full-length and truncated isoforms of
NTRK3 were PCR-amplified from BAC CTD-2508H23
with PfuTurbo® DNA polymerase (Stratagene, La Jolla,
CA), using primers containing an XbaI restriction site at
the 5’ end: forward 5’-acacactctagagtctgccccaaagaggtgta-
3’ and reverse 5’-acacactctagaccaaactgccttacagggttt-3’ for
the full-length isoform and forward 5’-acacactctagaaa-
taagccttcccggacatt-3’ and reverse 5’-acacactctagatg-
caaaatttccaaataagagg-3’ for the truncated isoform. PCR
fragments of 334 and 2110 bp respectively were purified,
XbaI-digested and cloned into an XbaI site located
downstream of the firefly luciferase reporter gene in the
pGL4.13 vector (Promega Corporation, Madison, WI).
Constructs were propagated in E. coli One Shot® TOP
10 cells (Invitrogen). Mutant reporter plasmids were
generated as previously described [19] using the Quik-
Change site-directed mutagenesis kit (Stratagene, La
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Jolla, CA, USA), with the wild-type pGL4.13 construct
as a template and primers carrying the desired point
mutations. The authenticity and orientation of the
inserts as well as the presence of the mutations were
confirmed by direct sequencing.
Cell culture and transfection
HeLa cells and SH-SY5Y neuroblastoma cells were main-
tained in Dulbecco’s Modified Eagle’s Medium supple-
mented with 10% fetal bovine serum, 2 mM L-glutamine,
100 units/ml penicillin and 100 μg/ml Streptomycin
(GIBCO™, Invitrogen). In the case of SH-SY5Y cells, fetal
bovine serum was heat inactivated for 45 min at 56°C
prior to use. Transfection with small RNAs was per-
formed with Lipofectamine 2000 (Invitrogen), using
either small RNAs that mimic endogenous mature miR-
NAs and the related negative controls (miRIDIAN™-
miRNA Mimics and miRIDIAN™miRNA Mimics
Negative Controls #2 and #4, Dharmacon Inc.) or
miRNA inhibitors and the corresponding negative
control (miRCURY LNA™ microRNA Inhibitors and
miRCURY LNA™ microRNA Inhibitor Negative Control
A, Exiqon). The cotransfection of plasmid DNA and
small RNAs into HeLa cells was optimized using a
GFP-containing plasmid (pEGFP-C1, Clontech) and a
commercially available GFP-specific siRNA (Ambion),
obtaining a transfection efficiency of over 80%. Transfec-
tion of SH-SY5Y cells with miRNA mimics was opti-
mized and monitored in each experiment using a
fluorescein-labeled double-stranded RNA oligomer
(siGLO Green Transfection Indicator, Dharmacon).
Optimal efficiency was obtained at a concentration of
50-200 nM and miRNA mimics as well as miRNA inhibi-
tors were ultimately used at 100 nM.
Luciferase activity assay
HeLa cells were seeded at 1.3 × 104 cells/well in 96-well
plates and cotransfected 24 h later with the Firefly repor-
ter constructs described above or the empty pGL4.13
vector (10-24 ng), the Renilla reporter plasmid pGL4.75
(3 ng) and the appropriate miRNA mimic (30 nM). The
activity of Firefly and Renilla luciferases was determined
24 h after transfection using the Dual-Glo™ Luciferase
Assay System (Promega). Relative reporter activity was
obtained by normalization to the Renilla luciferase activ-
ity. In order to correct for vector-dependent unspecific
effects, each relative reporter activity was normalized to
the empty vector cotransfected with the corresponding
miRNA. Results were then compared to the mean of the
two negative controls. Each experiment was done in tri-
plicate and at least three independent experiments were
performed for each miRNA. Statistical significance was
determined using Student’s t test (p < 0.05).
Western blotting
For the analysis of NTRK3 expression during RA-
induced differentiation, SH-SY5Y cells were treated with
10 μM all-trans-RA and harvested at time 0 (untreated),
day 3, day 6 and day 10 of RA treatment. For TR-
NTRK3, undifferentiated SH-SY5Y cells were plated at
2 × 105 cells per well in 6-well plates and transfected
24 h later with 100 nM miRNA mimic; 72 h after trans-
fection cells were lysed and analyzed by western blot-
ting. For FL-NTRK3, SH-SY5Y cells were differentiated
with 10 μM all-trans-RA, plated in 6-well plates at a
concentration of 3 × 105 cells per well at day 3 of RA
treatment, transfected with 100 nM miRNA mimic at
day 4 of RA treatment and analyzed 72 h after transfec-
tion (day 7 of RA treatment).
For protein extraction, cells were rapidly rinsed with
ice-cold PBS and solubilized with RIPA buffer: 50 mM
Tris-HCl pH 7.4, 150 mM NaCl, 2 mM EDTA, 0.1%
SDS, 1% Nonidet P 40, 1% sodium deoxycholate, 1 mM
Na3VO4, 1 mM PMSF, 50 mM NaF and 1× protease
inhibitors (Complete Mini, EDTA-free, Roche). Cells
were then scraped off, incubated on ice for 15 min and
centrifuged at 12000 rpm for 15 min. Samples were
resolved in NuPAGE® 4-12% Bis-Tris polycrylamide gels
using the NuPAGE® MES SDS Running Buffer and
transferred to nitrocellulose membranes using the
iBlot™Dry Blotting System (Invitogen). Before blotting,
gels were equilibrated in 100 ml equilibration buffer (2×
NuPAGE® Transfer Buffer, 10% methanol and 1:1000
NuPAGE® Antioxidant) for 20 min at room temperature
(RT; all NuPAGE® products are from Invitrogen).
Immunodetection was performed using the ODYSSEY®
infrared imaging system (LI-COR® Biosciences), follow-
ing the manufacturer’s instructions for two-color wes-
tern blotting. This detection system allows the precise
quantification of low-abundance proteins (as is the case
of TR-NTRK3) for which chemiluminescence is not
enough sensitive and accurate, and has the advantage
that the signal generated by the proteins on the mem-
brane is measured in a static state. Membranes were
blocked in ODYSSEY® blocking buffer for 1 h at RT and
incubated with the appropriate primary antibody (Ab)
for 1 h at RT (anti-TrkC goat polyclonal IgG, Upstate,
catalog number 07-226; anti-Bcl-2 (N-19), Santa Cruz,
catalog number sc-492; anti-Caspase-3, Millipore, cata-
log number 06-735; anti-Caspase-9, Cell Signaling, cata-
log number 9508). As a loading control, membranes
were simultaneously incubated with an anti-GAPDH Ab
(anti-GAPDH mouse monoclonal Ab, Chemicon, catalog
number MAB374). Blots were subsequently probed
with the appropriate fluorophore-labeled secondary
antibodies (LI-COR® Biosciences) and finally scanned on
an ODYSSEY® infrared scanner. Fluorescent bands
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were quantified using the ODYSSEY® software. Each
experiment was repeated at least four times; data are
reported as means ± SE and statistical significance was
determined using Student’s t test.
For the analysis of ERK phosphorylation, differentiated
cells were seeded and transfected as explained above;
72 h after transfection cells were rinsed twice with
serum-free medium, incubated with serum-free medium
for 5 h and then acutely stimulated for 10 min with
30 ng/mL neurotrophin-3 (Alomone Labs). Cells were
then lysed in 50 mM Tris-HCl pH 7.4, 50 mM NaF,
10 mM sodium pyrophosphate and 0.005% Triton
X-100. After transfer, membranes were incubated with
an anti-phopsho-ERK (Anti-MAP kinase, activated
mouse monoclonal Ab, Sigma, catalog #M9692) and an
anti-pan-ERK Ab (Anti-p44/42 MAP kinase rabbit poly-
clonal Ab, Cell Signaling, catalog # 9102). To make sure
that the quantification was accurate in each WB, a gra-
dient (5, 10 and 15 μg) of one of the control samples
was loaded on each gel. The gradients of FL-NTRK3,
TR-NTRK3 and GAPDH were quantified by densitome-
try, and the corresponding standard curve equations
were calculated for each WB; blots were considered reli-
able only if standard curves showed a correlation coeffi-
cient (R2) > 0.9 (Additional file 1). Standard curve
equations were then applied to the densitometry counts
of each sample for quantification.
miRNA expression analysis using custom microarrays
(Agilent, 11k)
Total RNA, including short RNAs, was extracted from
HeLa and SH-SY5Y cells using the miRNeasy® Mini Kit
(QIAGEN). miRNA expression in HeLa and SH-SY5Y
cells was analyzed using custom 11k oligonucleotide
microarrays (Agilent Technologies), including probes for
the 325 known human miRNAs according to Sanger miR-
Base release 7.1. The expression values obtained were
compared with results reported in other studies [20,21],
and the general correlation was good; however, to avoid
possible false results due to a failure in the hybridization
of specific individual probes, we eliminated from sub-
sequent analysis those miRNAs whose expression values
were discordant with the other studies. Negative controls
included probes for 20 Bacillus subtilis-specific sequences
and 20 rare non-human sequences. Two μg of total RNA
were labeled with Hy5™or Hy3™fluorescent labels using the
miRCURY™LNA microRNA Labelling kit (Exiqon), follow-
ing the manufacturer’s instructions. Pairs of labeled sam-
ples were hybridized to dual-channel microarrays for 40 h
at 55°C using Agilent hybridization reagents. Microarray
images were quantified using the GenePix 6.0 (Axon) soft-
ware; only spots with signal intensities twice above the
local background and not saturated were considered reli-
able and used for subsequent analysis. Extracted intensities
were subtracted from the local background and the log2
ratios were normalized in an intensity-dependent fashion.
Statistical analyses were performed using the MMARGE
tool.
Whole-genome expression analysis using beadchip
microarrays
Total RNA samples obtained from four independent
experiments (SH-SY5Y cells transfected with miR-128
and the related negative controls) were analyzed on
HumanRef-8 BeadChips from Illumina, which target
24,500 well-annotated RefSeq transcripts. Starting from
200 ng of total RNA, biotin-labeled cRNA was synthe-
sized and hybridized according to the manufacturer’s
instructions. Data were analyzed using the Array File
Maker (AFM) 4.0 software package. The whole genome
microarray data obtained here are part of a larger pro-
ject that is still ongoing. These results will be deposited
in MIAME format in the ArrayExpress public repository
once the experiment is completed.
Real-time quantitative RT-PCR
DNase-treated RNA extracted from transfected cells was
retrotranscribed with the SuperScript™III First-Strand
Synthesis System for RT-PCR (Invitrogen). RNA levels
of the full-length and truncated isoforms of NTRK3
were analyzed by real-time quantitative RT-PCR using
SYBR Green I (Roche), following the manufacturer’s
instructions. Reactions were performed with the Light-
Cycler® 480 Instrument (Roche) in 384-multiwell plates.
Specific primers were designed for the two NTRK3 iso-
forms (FL-NTRK3 forward 5’-cagccatggttccaactctc-3’,
FL-NTRK3 reverse 5’-ccagcatgacatcgtacacc-3’, TR-
NTRK3 forward 5’-tccagagtggggaagtgtct-3’, TR-NTRK3
reverse 5’-ccatggttaagaggcttgga-3’) and for GAPDH
(forward 5’-ctgacttcaacagcgacacc-3’, reverse 5’-
ccctgttgctgtagccaaat-3’), which was used as housekeep-
ing gene. All amplicons were ~100 bp in length, and
forward and reverse primers were located in different
exons. Thermal cycling was performed as follows: one
pre-incubation cycle at 95°C for 10 min (ramp rate:
4.8°C/s); 45 amplification cycles at 95°C for 10 sec, 57°C
for 30 sec and 72°C for 5 sec (ramp rates: 4.8, 2.2 and
4.8°C/s). The expression levels of miR-128 in different
human tissues and in SH-SY5Y cells were analyzed
using the TaqMan® MicroRNA Assays, following the
manufacturer’s instructions.
Cell counting
Cells cultured on 6-well plates and transfected with
miR-128, the TR-NTRK3-specific siRNA (sense 5’-gagu-
cuaugccuuuggcaatt-3’, antisense 5’-uugccaaaggcauaga-
cuctt-3’, Gene Link) and the related negative controls
were trypsinized and resuspended in 1 mL DMEM;
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100 μL of each sample were then diluted in 10 mL of
Coulter Isoton II diluent (Beclman Coulter) and counted
using a Z2™ Series Coulter Particle Count and Size
Analyzer (Beckman Coulter).
Flow cytometry
SH-SY5Y cells transfected with miR-128 and the related
negative controls were trypsinized and resuspended in
PBS 72 h after transfection cells. Samples were examined
using a BD FACSCanto Flow Cytometer and the BD
FACSDiva software (BD Biosciences). A two-parameter
forward/side scatter (FSC/SSC) analysis was performed
recording 5000 events in each analysis.
Computational methods
Three web-based miRNA target prediction methods were
used: miRanda (http://www.microrna.org, 2005 release;
[22]), TargetScan (http://www.targetscan.org, releases
2.0, 2.1, 3.0 and 3.1; [15]) and PicTar (http://pictar.mdc-
berlin.de; [23]). Genomic coordinates were according to
the human assembly release of March 2006 (H. sapiens
hg18). Sequences were obtained from the University of
California Santa Cruz (UCSC) Genome Browser http://
www.genome.ucsc.edu. Sequence analysis was performed
using the 4peaks software http://mekentosj.com/4peaks/
and Multalin http://multalin.toulouse.inra.fr/multalin/.
Primers were designed using the Primer3 software http://
frodo.wi.mit.edu/cgi-bin/primer3/primer3.cgi and PCR
annealing temperatures were calculated with the Opti-
mase ProtocolWriter™ http://mutationdiscovery.com.
Pathway analysis from microarray expression data was
performed with the Ingenuity Pathway Analysis Software
(IPA) version 6.3 http://www.ingenuity.com.
Results
Functional screening of miRNA target sites in NTRK3
The full-length and the truncated isoform of NTRK3
were searched for putative target sites with three widely
used miRNA target prediction programs - miRanda,
TargetScan and PicTar. Taking into account the 325
human miRNAs annotated in the miRbase database at
the time of the analysis (version 7.1, October 2005) we
could identify 3 miRNAs predicted to target the full-
length isoform and 29 miRNAs predicted to target the
truncated isoform (Table 1).
The entire 3’UTRs of the full-length and truncated
isoforms of NTRK3 (178 and 1981 bp, respectively) were
cloned immediately downstream of the firefly luciferase
open reading frame in the pGL4.13 plasmid, and the
resulting constructs were designated pGL4.13-FL and
pGL4.13-TR. The renilla reporter plasmid pGL4.75 was
used to control for transfection efficiency. A total of 55
miRNAs and 2 non-targeting controls were tested on
Table 1 Tested miRNAs and predicted target
miRNA FL-NTRK3 TR-NTRK3
hsa-let-7b† M(1), T(1)
hsa-let-7e† M(1)
hsa-miR-1 NP NP
hsa-miR-9# T(1)
hsa-miR-10a NP NP
hsa-miR-15a NP NP
hsa-miR-16 NP NP
hsa-miR-17-3p NP NP
hsa-miR-17-5p† T(2)
hsa-miR-18a* M(1)
hsa-miR-18a* NP NP
hsa-miR-20a† T(2)
hsa-miR-24# T(1)
hsa-miR-30e-3p NP NP
hsa-miR-30e-5p NP NP
hsa-miR-93† T(1)
hsa-miR-103 NP NP
hsa-miR-106a† T(2)
hsa-miR-106b† T(2)
hsa-miR-107 NP NP
hsa-miR-125a§ M(2), T(2)
hsa-miR-125b M(2)
hsa-miR-128† M(1), T(1)
hsa-miR-133a# M(1)
hsa-miR-141 NP NP
hsa-miR-149# M(1), T(1)
hsa-miR-151-3p M(1)
hsa-miR-182 NP NP
hsa-miR-185 M(1), P(1)
hsa-miR-188 M(1)
hsa-miR-198 M(1)
hsa-miR-200a NP NP
hsa-miR-200b NP NP
hsa-miR-204# M(1), T(1)
hsa-miR-206 NP NP
hsa-miR-211# M(1), T(1)
hsa-miR-221 NP NP
hsa-miR-296 M (1)
hsa-miR-324-5p§ M(1), T(1)
hsa-miR-326 M(2)
hsa-miR-330-3p¥ M(2), T(2)
hsa-miR-331 M(2)
hsa-miR-340 M(1)
hsa-miR-345¥ T(1)
hsa-miR-374 NP NP
hsa-miR-384§ T(1)
hsa-miR-412 M(1)
hsa-miR-422a# M(1), T(1)
hsa-miR-449 M(1)
hsa-miR-485-3p§ T(1)
hsa-miR-509¥ M(1), T(2)
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both pGL4.13-FL and pGL4.13-TR. Tested miRNAs
(Table 1) included the 32 mentioned above; 6 additional
miRNAs that appeared in more recent versions of the
miRbase database and had putative target sites in the
truncated isoform (miR-485-3p, miR-509, miR-617,
miR-625, miR-765 and miR-768-5p) were also included
because allelic variants were found in their target sites
after re-sequencing of patients with anxiety disorders
[19]. Eleven out of the 35 miRNAs were predicted to
regulate the truncated isoform by more than one
method, and at least 7 were conserved target sites for
miRNA families broadly conserved among vertebrates
(Table 1). Finally, 17 miRNAs with no predicted target
sites according to the interrogated methods were also
analyzed for comparison.
The specific luciferase activity of the pGL4.13-FL con-
struct was significantly decreased by 2 miRNAs pre-
dicted to target the full-length isoform (miR-151-3p and
miR-185, Figure 1A). The strongest repression was
observed with miR-185 (54% reduction), followed by
miR-151-3p (20%). In the case of pGL4.13-TR, the luci-
ferase activity was significantly reduced by 8 miRNAs
(Figure 1A), all of which were predicted by at least one
program: miR-128, miR-324-5p, miR-330, miR-485-3p,
miR-509, miR-625, miR-765 and miR-768-5p. The most
conspicuous inhibition was detected with miR-625 (62%
reduction), miR-509 (47%) and miR-128 (32%), while
the other five miRNAs gave a reduction ranging
between 13% and 30%.
Since multiple target sites in the same 3’UTR are
thought to be cooperative and to increase the efficacy of
miRNA inhibition, we analyzed whether the cotransfec-
tion of different miRNAs repressing pGL4-13-TR could
lead to a synergistic effect and a more dramatic reduc-
tion in luciferase activity. Thirteen combinations of two
miRNAs were tested, but we could not detect a signifi-
cant decrease in luciferase expression compared with
the corresponding miRNAs taken individually; a combi-
nation of the three most effective miRNAs - miR-128,
509 and 625 - was also analyzed and no synergistic
effect was observed (Additional file 2).
miRNA-mediated regulation of endogenous NTRK3 in
neuroblastoma cells
SH-SY5Y neuroblastoma cells were used to investigate
whether miRNAs causing a significant decrease in luci-
ferase activity were also able to downregulate endogen-
ous NTRK3. Upon exposure to retinoic acid (RA),
SH-SY5Y cells reduce their growth rate and differentiate
by extending neurites into cells that are biochemically,
ultrastructurally and electrophysiologically similar to
neurons [24]. Furthermore, RA treatment has been
shown to induce the appearance of functional FL-
NTRK3 receptors in this cell line [25].
We characterized the expression of NTRK3 in SH-
SY5Y cells at different time points during RA exposure
by western blotting. As previously described for
another neuroblastoma cell line [17], we could observe
an increase in the levels of the full-length isoform and
a decrease in the truncated isoform. Full-length protein
levels were ~2.5-fold higher after three days of RA
treatment, ~4-fold higher after six days and reached up
to ~8-fold after ten days. On the other hand, the
expression of the truncated isoform was reduced by
approximately 50% after three days of exposure, and
kept decreasing very slightly through day 10 (Figure 2).
Given these expression profiles, untreated cells were
used to study the regulation of the truncated isoform,
and RA-differentiated cells were used for the full-
length isoform.
The endogenous expression of 7 luciferase-validated
miRNAs was also analyzed in SH-SY5Y cells, using cus-
tom oligonucleotide microarrays (Table 2). The expres-
sion of these miRNAs was in general very low, making
miRNA overexpression, rather than the use of miRNA
antagonists, the method of choice to analyze the regula-
tion of endogenous NTRK3 in this cell system. Lucifer-
ase-validated miRNAs were therefore transfected into
either undifferentiated (miR-128, miR-324-5p, miR-330,
miR-485-3p, miR-509, miR-625, miR-765 and miR-768-
5p) or differentiated SH-SY5Y cells (miR-151-3p and
miR-185), and protein levels were assessed by western
blotting 72 h after transfection. In agreement with the
luciferase assay data, FL-NTRK3 levels were significantly
reduced by miR-151-3p (34%); a slight inhibition was
also observed with miR-185, but did not reach statistical
significance (Figure 3A). To investigate whether such
inhibition of FL-NTRK3 was able to affect the efficiency
of NT3-induced signaling, we analyzed ERK1/2 phos-
phorylation by acutely stimulating transfected cells with
NT3 after serum starvation. ERK phosphorylation was
used as a readout for the activation of the Ras/MAPK
pathway, which is triggered by stimulation of full-length,
kinase-active NTRK receptors [26]. We could detect a
reduction in ERK phosphorylation with miR-151-3p but
not with miR-185 (Figure 3B), which is consistent with
Table 1 Tested miRNAs and predicted target (Continued)
hsa-miR-617¥ T(1)
hsa-miR-625¥ T(2)
hsa-miR-765¥ T(1)
hsa-miR-768-5p¥ T(1)
M, miRanda; T, TargetScan; P, Pictar; NP, not predicted for either isoform; †
and #, conserved
sites and poorly conserved sites for miRNA families broadly
conserved among vertebrates, respectively; §, poorly
conserved sites for miRNA families conserved only among mammals;
¥, poorly conserved sites or poorly conserved miRNA families.
The number of predicted sites is indicated in brackets.
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the reduction observed in the levels of FL-NTRK3 after
overexpression of miR-151-3p.
As for TR-NTRK3 (Figure 3C), a significant downre-
gulation, ranging between 20% and 30%, was observed
with miR-128, miR-485-3p, miR-765 and miR-768-5p;
the strongest repression was caused by miR-128 (32%
reduction) and miR-485-3p (30%). Three natural muta-
tions occurring in the 3’UTR of TR-NTRK3 had been
previously identified, which fall within the predicted
binding sites of these four miRNAs [19]: ss102661458 at
the binding sites for miR-768-5p (A-> C at the +3 seed
region position) and miR-128 (+13 position),
rs28521337 at the binding site for miR-485-3p (G-> C
at the +3 seed region), and ss102661460 at the binding
site for miR-768-5p (C-> G at the +3 seed region). We
generated pGL4.13-TR point mutants that resemble
these naturally occurring mutations and could observe a
significant recovery of luciferase activity in mutant
Figure 1 Functional screening of NTRK3 miRNA target sites using a luciferase-based assay. A. Luciferase assay results: FL-NTRK3 and TR-
NTRK3 regulation by miRNAs. HeLa cells were cotransfected with pGL4.13-FL or pGL4.13-TR and the indicated miRNA mimics (C = Control).
Luciferase activities were measured 24 h after transfection; firefly luciferase activity was normalized to Renilla luciferase activity, and results from
at least three independent experiments are presented as means ± SE. Only statistically significant results are shown (p < 0.05). B. The relative
location of the target sequences of validated miRNAs in the 3’UTRs of FL-NTRK3 and TR-NTRK3 is shown with an enlargement of overlapping
target sites, where sequence pairing to the 3’UTRs (lines) and miRNA seed regions (underlines) are indicated.
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constructs (Figure 4), which supports the predicted
direct miRNA-mRNA binding interactions. The remain-
ing four miRNAs (miR-324-5p, miR-330-3p, miR-509
and miR-625) caused a slight reduction in the expres-
sion levels of the truncated isoform of NTRK3 (maxi-
mum 15%), but none of them reached statistical
significance. In the case of miR-128, the miRNA that
caused the strongest reduction in TR-NTRK3 levels, we
performed antisense experiments using LNA miRNA
inhibitors. Blocking endogenous miR-128, we could
observe a slight increase (over 10%) in the levels of TR-
NTRK3 compared with the control (Additional file 3);
however, the difference did not reach statistical signifi-
cance, probably due to the low basal expression of miR-
128 in this cell system.
Finally, full-length and truncated NTRK3 transcripts
were quantified by real-time quantitative RT-PCR after
miRNA overexpression, using isoform-specific primers.
mRNA levels were not affected by any of the regulating
miRNAs, indicating that they do not act by destabilizing
NTRK3 transcripts and suggesting that the observed
downregulation is achieved through translational
repression.
miR-128 overexpression affects the morphology and
number of SH-SY5Y cells
After transfection with miRNA mimics, cells were exam-
ined under a phase-contrast microscope to check for
possible alterations induced by miRNA overexpression.
While in most cases there were no appreciable differ-
ences, considerable changes were observed after trans-
fection with miR-128 (Figure 5A): cells acquired
rounded bodies with shorter neurites, the overall cell
size looked smaller than control cells and the culture
confluence appeared to be higher, suggesting an increase
in the total number of cells. Given that miR-128 down-
regulates TR-NTRK3, it was reasonable to speculate that
the repression of this variant could be responsible for at
least part of the observed effects. Cells were therefore
transfected with an siRNA directed against TR-NTRK3,
which targets an isoform-specific sequence located
within the 3’UTR region and reduces TR-NTRK3 levels
by approximately 25% - a degree of repression compar-
able to that observed with miR-128. Interestingly, the
morphology of cells was similar to that described
for miR-128 (Figure 5B), supporting the hypothesis
that TR-NTRK3 plays a part in the morphological
phenotype. In order to characterize these changes, two-
parameter forward/side scatter (FSC/SSC) flow cytome-
try was performed, revealing no shift in the population
of cells transfected with miR-128 (Figure 6A). This indi-
cates that there is no variation in the actual size or cyto-
plasmic complexity of cells and that the observed
alterations are due to other factors, possibly involving a
modification of the adhesive properties or in the motility
of the cell. Finally, transfected cells were counted with a
Coulter cell counter, showing that the total number of
cells in plates transfected with miR-128 was 27% higher
than in control plates (Figure 6B).
miR-128 is a brain-enriched miRNA, whose expression
has been shown to correlate and increase with neuronal
differentiation [27,28]. The expression of miR-128 was
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Figure 2 Characterization of the expression of NTRK3 in RA-differentiated SH-SY5Y cells. A. Immunoblotting of the full-length and
truncated isoforms of NTRK3 in SH-SY5Y cells treated with RA for the indicated times. GAPDH was used as a loading control. B. Protein levels
were quantified by densitometry and are reported as arbitrary units relative to untreated cells.
Table 2 miRNA expression levels in HeLa and SH-SY5Y
cells
miRNA HeLa Untreated SH-SY5Y Differentiated SH-SY5Y
(RA 6 days)
miR-128 2.3 5.1 7.5
miR-151-3p 1.5 3.9 4.8
miR-185 3.7 4.6 4.7
miR-324-5p 1.3 1.1 1.6
miR-330 1.8 6.2 6.7
miR-485-3p 1.1 7.9 7.9
miR-509 1.1 3.3 3.3
RA, retinoic acid. Expression levels are indicated relative to background signal.
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Figure 3 Analysis of miRNA-mediated regulation of endogenous NTRK3 in neuroblastoma cells. A. Western blot analysis of NTRK3 levels
in RA-differentiated cells transfected with mimics targeting FL-NTRK3; NTRK3 levels are reported relative to control cells. B. Analysis of ERK1/2
phosphorylation after acute stimulation of differentiated SH-SY5Y cells with NT3. Basal phosphorylation in unstimulated cells is also shown (-NT3).
C. NTRK3 levels in undifferentiated cells transfected with mimics targeting TR-NTRK3. Data from four independent experiments are presented as
means ± SE (*p < 0.05).
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analyzed by real-time quantitative RT-PCR in a set of
human tissues (adult brain, colon, heart, kidney, liver,
lung, ovary, skeletal muscle, spleen, testis, thymus and
placenta) as well as in SH-SY5Y cells at different stages
of RA treatment. The analysis confirmed that miR-128
is strongly expressed in the brain, and high levels were
also detected in skeletal muscle, followed by thymus and
kidney (Figure 7A). In SH-SY5Y cells, in agreement with
the miRNA microarray experiment described before,
miR-128 showed low levels of expression, with average
crossing point (Ct) values ranging from ~33 to ~35.
Nevertheless, we could indeed observe an increase in
miR-128 expression upon RA treatment (Figure 7B).
This change in miR-128 levels, also observed by micro-
array analysis, is consistent with the hypothesis that it
contributes to the repression of TR-NTRK3 during RA-
mediated differentiation of SH-SY5Y cells.
Transcriptome analysis of SH-SY5Y cells transfected with
miR-128
In order to gain insight into the role of miR-128, the
effects of its overexpression were further analyzed using
whole genome expression microarrays (Illumina’s
HumanRef-8 v3.0 beadchips). Considering a fold-change
(FC) cutoff of 1.2 and a q-value <5, we could identify a
total of 183 deregulated genes after miR-128 overexpres-
sion in SH-SY5Y cells - 116 downregulated and 67
upregulated - with a maximum FC of ~1.8 for upregu-
lated genes and -2 for downregulated genes. The top ten
upregulated and downregulated genes are listed in
Tables 3 and 4, respectively. Interestingly, among them
are several genes implicated in apoptosis, cell death/sur-
vival and proliferation, with a general tendency for those
leading to cell death to be downregulated and for those
leading to survival to be upregulated. The most striking
example is BCL2 (FC = 1.69), a well-known antiapopto-
tic gene that inhibits caspase activity. The upregulation
Figure 4 Effect of miRNA overexpression on allelic variants at
the 3’UTR of TR-NTRK3. Luciferase activity of wild-type (pGL4-WT)
and mutated (pGL4-MUT) TR-NTRK3 constructs corresponding to
allelic variants ss102661458, rs28521337 and ss102661460
cotransfected with the indicated miRNA mimics. Results from at
least three independent experiments are presented as means ± SD
(*p < 0.05).
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Figure 5 Phase-contrast micrographs of undifferentiated SH-
SY5Y cells. A. Cells were transfected with a non-targeting control
(A,B,C) and with miR-128 (D,E,F); morphological changes (rounded
bodies, shorter neurites and smaller cell size) were observed in cells
transfected with miR-128. B. Cells were transfected with a non-
silencing control (A,B) and with an siRNA directed against the
truncated isoform of NTRK3 (C,D). The morphology of cells
transfected with the siRNA resembles that of cells transfected with
miR-128.
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of BCL2 in miR-128-transfected cells could explain the
observed increase in cell number, which is consistent
with enhanced apoptosis inhibition. Also interesting is
PAIP2 (FC = -2.03), a translational repressor that inhi-
bits the Vascular Endothelial Growth Factor (VEGF), a
potent mitogen and survival factor with neuroprotective
functions in the brain. The deregulation of other genes
like NGFRAP1, PRSS3, TRAIF3IP2, CREB3L2 and of the
proapoptotic factors TXNIP (Thioredoxin Interacting
Protein, FC = -1.38) and DAP3 (Death Associated
Protein 3, FC = -1.36) follows the same trend. Other
strongly deregulated genes are involved in vesicular
transport, like DYNC1I1, and in cytoskeletal organization
like TMSB10, TRAPPC4 and VBP1 (Table 3 and 4).
This is in accordance with the observed morphological
phenotype and with the involvement of TR-NTRK3 in
membrane remodelling, actin reorganization and cell
movement [12].
The 183 genes deregulated upon miR-128 overexpres-
sion, with the corresponding expression values, were
uploaded into the Ingenuity Pathway Analysis software,
and the program was interrogated about biological func-
tions, canonical pathways and molecular networks that
could be affected. We found associations with biological
functions such as cell cycle, cancer, neurological disease
and cell death (-log(p-value) >3) and with metabolic
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Figure 6 Characterization of cells transfected with miR-128 and a TR-NTRK3-specific siRNA. A. Two-parameter forward/side scatter (FSC/
SSC) flow cytometry analysis of SH-SY5Y cells transfected with a non-targeting control and miR-128. No profile shift was observed. B. Counting
of undifferentiated SH-SY5Y cells transfected with miR-128, the a TR-NTRK3-specific siRNA and the corresponding negative controls. Results from
three independent experiments are reported as means ± SE, relative to the respective controls (*p < 0.05).
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canonical pathways (-log(p-value) >3). Enzymes impli-
cated in these pathways show a marked predominance
of downregulation over upregulation, indicating that
metabolic processes may in general be inhibited or
impaired in miR-128-transfected cells. Interestingly, the
molecular network showing the highest percentage of
deregulated genes has BCL2 as one of its central nodes
and is associated with cancer, gene expression and neu-
rological disease (Network 1, Figure 8).
Finally, microarray results were compared to target
predictions, in order to check whether any of the
deregulated genes could potentially be direct targets of
miR-128; such genes would undergo miRNA-mediated
regulation through mRNA cleavage rather than transla-
tional repression. Table 5 shows the intersection of the
183 genes deregulated by miR-128 overexpression (FC
cutoff of 1.2 and a q-value <5) and the putative target
genes predicted by TargetScan. Of 669 total predicted
miR-128 targets, 38 were deregulated (5.7%), a number
that is higher than expected by chance (chi square test,
p < 10-6) and indicates a significant enrichment for
deregulated genes among predicted targets. As expect-
able, there was a huge predominance of downregulation
over upregulation, with just one upregulated gene out
of 38.
Overexpression of miR-128 upregulates BCL2
BCL2 has no predicted target sites for miR-128 and, as
previously mentioned, resulted to be upregulated upon
miR-128 overexpression (FC = 1.69, third most upre-
gulated gene) in our microarray experiment. Such
upregulation was validated by western blotting, which
showed an increase of approximately 1.5-fold at the
protein level (Figure 9A) - similar to that observed by
microarray for the transcript. The possible effect of the
upregulation of BCL2 on the activation of apoptotic
markers, such as caspase-3 and caspase-9, in cells
transfected with miR-128 was also analyzed by western
blotting. As shown in Figure 9B, the active forms of
both caspases are practically undetectable, indicating
Table 3 Top 10 upregulated genes upon miR-128 overexpression in SH-SY5Y cells
GENE FC FUNCTION
DYNC1I1 1.781 Microtubule-based vesicular trafficking;retrograde
axonal transport of signaling endosomes containing
neurotrophins and associated downstream kinases
HMGCS1 1.728 Lipogenesis and biosynthesis of cholesterol
BCL2 1.689 Regulation of cell death and
caspase activity; antiapoptotic
CREB3L2 1.652 Transcription factor of the CREB3 family;
astrocyte proliferation in response
to inflammation and trauma (gliosis)
TRAF3IP2 1.558 Activation of the transcription factor NFkB;
implicated in malignant processes and in the
regulation of the apoptotic response; mediates the
antiapoptotic effect of TGF-beta and TNF-alpha
ISLR2 1.544 Integral membrane protein
KLF6 1.544 Zinc finger transcription factor; adipogenesis
and inhibition of cellular growth
PRICKLE1 1.508 May regulate neurite formation
during brain development
ADIPOR1 1.504 Component of the energy homeostatic mechanism;
increases fatty acid oxidation and glucose uptake;
may participate in the control higher brain functions
PRSS3 1.498 Encodes mesotrypsin, a brain-specific
trypsin form thought to protect neural
cells from apoptotic cell death
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that the basal level of apoptosis in SH-SY5Y cells is
already low; as a consequence, it was not possible to
appreciate any decrease in the activation of the two
caspases. However, although better known as an antia-
poptotic factor, BCL2 also plays a role in the regula-
tion of the cell cycle, which appears to be at least in
part separate from its antiapoptotic function. It has
been shown that BCL2 has an antiproliferative effect,
driving cells into enhanced G0 arrest. Enhanced G0
could possibly explain the increase in cell number
associated with miR-128 and is compatible with the
general downregulation of metabolic pathways indi-
cated by the microarray analysis. MTT assays per-
formed on SH-SY5Y cells revealed no change in
total mitochondrial activity after transfection with
miR-128 (data not shown) despite the larger number
of cells, again in agreement with a general reduction of
metabolic activity, which is typical of the quiescent
state.
Discussion
In this study we explore how miRNAs take part in the reg-
ulation of two isoforms of the neurotrophin-3 receptor
NTRK3, which present non-overlapping 3’UTRs. We
demonstrate that the two isoforms are targeted by differ-
ent sets of miRNAs, providing new evidence for a role of
miRNAs in determining the balance among different
splice variants of a gene. In fact, we identify one miRNAs
regulating the full-length isoform of NTRK3 (miR-151-3p)
and 4 miRNAs regulating the truncated isoform (miR-128,
miR-485-3p, miR-765 and miR-768-5p).
Our approach followed two steps: a first screening of
miRNAs with predicted targets in the 3’UTR of either
isoform, performed in HeLa cells using luciferase con-
structs, and a subsequent validation of the ability of
luciferase-positive miRNAs to repress endogenous
NTRK3 receptors in SH-SY5Y neuroblastoma cells.
Upon exposure to RA, SH-SY5Y differentiate into cells
that are similar to neurons [24]; the presence of
Table 4 Top 10 downregulated genes upon miR-128
GENE FC FUNCTION
TMSB10 -1.583 Organization of the cytoskeleton, cell motility and spreading:
binds to actin monomers and inhibits actin polymerization;
anti-apoptotic action in chickembryo motoneurons
TRAPPC4 -1.589 Vesicular transport from endoplasmic reticulum to golgi;
possible role in postsynaptic membrane trafficking
G6PC3 -1.595 Regulation of glucose homeostasis: catalyzes
hydrolysis of G6P to glucose and phosphate
VPB1 -1.617 Chaperone protein; maturation of the cytoskeleton
and morphogenesis; possible role in the
transport and correct localization of the tumor
suppressor von Hippel-Lindau (VHL) protein
NGFRAP1 -1.637 p75NTR-associated protein; mediates
apoptosis in response to NGF
PKIA -1.699 PKA inhibition
YWHAB -1.713 Member of the brain-abundant 14-3-3 protein
family; may play a role in linking
mitogenic signaling and the cell cycle machinery
PAIP2 -2.034 Translational repressor; acts on VEGF
(Vascular Endothelial Growth Factor)
CHGB -2.050 Secretory protein expressed in neuronal cells;
guides and sorts the secretion of neuropeptides
TROVE2 -2.069 RNA-binding protein; major autoantigen
in patients suffering from autoimmune diseases;
binds small RNAs of unknown function (Y RNAs)
and misfolded noncoding RNAs; possible function
in the degradation of defective RNAs
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FL-NTRK3 receptors after RA stimulation had pre-
viously been demonstrated in this cell system [25],
where we could well characterize the expression of both
NTRK3 isoforms.
If we compare the results obtained with the two stra-
tegies, 5 out of 10 (50%) luciferase-positive miRNAs
were validated on endogenous NTRK3. Given that the
constitutive expression of the remaining 5 miRNAs is
similarly low in both HeLa and SH-SY5Y cells, we could
rule out the possibility that high levels of endogenous
miRNAs in SH-SY5Y cells affected the results of the
validation, making the overexpression of miRNA mimics
Figure 8 Molecular network showing the highest percentage of genes altered by the overexpression of miR-128. Downregulated and
upregulated genes are shown green and red, respectively. The analysis was performed using the Ingenuity Pathway Analysis software.
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less effective; such rate of false-positives is probably
related with the artificial context in which the 3’UTRs
are inserted in the luciferase assay strategy.
One limitation of this study is that, due to the gener-
ally low expression levels of the analyzed miRNAs in
SH-SY5Y cells, the experiments were based on miRNA
overexpression, rather than inhibition of endogenous
miRNAs. It would be certainly interesting to analyze the
effect of miRNA inhibition in a different cell system
where the miRNAs of interest are highly expressed,
including cell lines where NTRK3 is not present and
where the inhibition of the regulating miRNAs might
indeed induce its expression. In addition, the levels of
the truncated isoform of NTRK3 were also low in SH-
SY5Y, and standard WB quantification by enhanced
chemiluminescence detection proved to be not enough
sensitive. We therefore used fluorescent detection,
employing fluorescently-labelled secondary antibodies
and an infrared imaging system, which allows the pre-
cise quantification of low-abundance proteins [29], and
has the advantage that the signal generated by the pro-
teins on the membrane is measured in a static state, as
opposed to the enzymatic reaction of chemilumines-
cence, which is dynamic and changes over time [30].
Given that the signal with this detection system is linear
and not exponential as in chemiluminescence, the differ-
ences between bands are less apparent but the quantifi-
cation by densitometry becomes much more accurate.
This allowed us to detect the subtle changes originated
by the overexpression of miRNAs.
Interestingly, miR-151-3p and miR-185 have partially
overlapping target sequences in the full-length isoform
and, in a similar way, miR-128, miR-509 and miR-768-5p
target the same segment of the 3’UTR of the truncated
isoform (Figure 1B). It is worth of notice that while both
miR-128 and miR-509 cause a strong reduction in lucifer-
ase activity (30-50%), only miR-128 seems to repress the
corresponding protein isoform in SH-SY5Y cells. Intrigu-
ingly, miR-128 is expressed in brain, whereas miR-509 is
not present in brain but shows a strong expression in
kidney and testis. This suggests that the binding of these
miRNAs to their target sequences might be mutually
exclusive, and that the regulation of NTRK3 by miRNAs
could be coordinated in a tissue specific fashion.
The second part of this study focused on miR-128,
one of the miRNAs repressing the truncated isoform.
Table 5 Target predictions and genes deregulated by
miR-128
GENE FC GENE FC
TROVE2 -2.07 PHB -1.27
PAIP2 -2.03 PPAP2B -1.26
YWHAB -1.71 ATP6V1A -1.25
PKIA -1.70 STAG1 -1.21
NGFRAP1 -1.64 PRKX -1.21
C1orf144 -1.62 RPS6KB1 -1.16
NGFRAP1 -1.61 CABLES2 -1.14
TMSB10 -1.58 EIF2S2 -1.13
UBE2E2 -1.58 RGL2 -1.10
SEC61A1 -1.56 SH3BGRL2* 1.34
GLTP -1.53 DAZAP2 -1.43
VANGL2 -1.52 FBXO33 -1.43
C12orf34 -1.51 VPS4B -1.43
UBE2N -1.50 PDHX -1.41
CASC3 -1.49 SLC39A11 -1.41
DCUN1D4 -1.48 ZZZ3 -1.30
WDR68 -1.46 E2F7 -1.28
RNF144 -1.46 GPAM -1.28
PPP1CC -1.44 PDIA5 -1.28
Overlapping between target predictions for miR-128 (TargetScan) and genes
deregulated by its overexperession. *Only one out of 38 deregulated and
predicted target genes was upregulated.
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miR-128 is a brain-enriched miRNA, whose expression
has been shown to positively correlate with neuronal
differentiation [27,28]. Furthermore, accumulation of
miR-128 has been detected in the hippocampus of
Alzheimer’s disease brains [31]. Here, we show that
the overexpression of miR-128 causes morphological
changes in SH-SY5Y cells, which resemble those
observed using an siRNA specifically directed against
TR-NTRK3. In accordance with the morphological
changes, as revealed by microarray analysis, miR-128
alters the expression of genes involved in cytoskeletal
organization, a process with which the truncated iso-
form has been related. These results suggest an involve-
ment of miR-128 in the organization of the cytoskeleton
through the regulation of NTRK3, possibly in coopera-
tion with other miR-128 targets.
Another consequence of the overexpression of miR-
128 in SH-SY5Y cells is an increase in cell number,
which is accompanied by the deregulation of genes
involved in apoptosis, cell death/survival and prolifera-
tion, with a remarkable upregulation of BCL2. BCL2
codes for an outer mitochondrial membrane protein
that blocks cytochrome c release from mitochondria and
inhibits caspase activity, suppressing apoptosis. However,
the analysis of caspase-3 and caspase-9 activation
revealed that in normal culture conditions there is vir-
tually no apoptosis in SH-SY5Y cells, making the
hypothesis of an increased inhibition of this process
unsuitable for our results. It would be therefore interest-
ing to analyze the effects of miR-128 in the presence of
apoptosis-promoting agents.
Besides apoptosis, BCL2 also plays a role in the regu-
lation of the cell cycle, having an antiproliferative effect
that drives cells into enhanced G0 arrest. This is
thought to promote cell survival, especially in unfavor-
able environments, since quiescent cells are more resis-
tant to killing than proliferating cells [32]. Although this
could be could be compatible with the increase in cell
number and with the general reduction of metabolic
activity observed in our analyses, further investigation is
needed to support this hypothesis and to exhaustively
evaluate the contribution of BCL2 to the observed phe-
notype, as well as that of other proliferation-regulating
genes whose expression is altered by miR-128.
Conclusions
The full-length and truncated isoforms of NTRK3 are
regulated by different sets of miRNAs, demonstrating
that the regulation of NTRK3 by microRNAs is isoform-
specific and indicating that neurotrophin-mediated pro-
cesses are strongly linked to microRNA-dependent
mechanisms. In addition, overexpression of the brain-
enriched miRNA miR-128 - one of the miRNAs that
regulates the truncated isoform of NTRK3 - causes
morphological changes in neuroblastoma cells and alters
the expression profile of genes involved in cytoskeletal
organization, apoptosis and cell proliferation, including
the anti-apoptotic factor BCL2. These findings open
new perspectives for the study of the physiological role
of miR-128 and its possible involvement in cell death/
survival processes.
Additional material
Additional file 1: WB of a protein gradient (A) with the
corresponding standard curves for TR-NTRK3 (B) and GAPDH (C). 5,
10 and 15 μg of a control sample were loaded on each protein gel and
standard curves were calculated for each immunoblot.
Additional file 2: Analysis of miRNA synergism in TR-NTRK3 using a
luciferase based assay. HeLa cells were cotransfected with pGL4.13-TR
and the indicated combinations of miRNA mimics (X axis, C = Control).
Luciferase activities were measured 24 h after transfection; firefly
luciferase activity was normalized to Renilla luciferase activity, and results
from at least three independent experiments are presented as means ±
SE.
Additional file 3: Representative WB experiment of SH-SY5Y cells
transfected with an anti-miR-128 LNA inhibitor and a control.
Although an increase in the levels of TR-NTRK3 was observed with the
anti-miR-128, the difference did not reach statistical significance (three
independent experiments were performed).
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